John F. Manzello President & CEO jmanzello@promosome

1. Promosome LLC, Introduction John F. ManzelloPresident & CEO jmanzello@promosome.com

2. Management Team John F. Manzello, President and CEO - Established & outstanding track record of 15 years in Director and Executive level management in business/commercial development, fully focused on the introduction of innovative science for bio-production within the biopharmaceutical industry. William J. Gedale, Chairman - Managing General Partner of NGN Capital. 35+ years of Operating Management & Investment experience. Funded a number of activities of The Scripps Research Institute.

3. Scientific Leadership Gerald M. Edelman, M.D., Ph.D.,is Chair of Neurobiology at The Scripps Research Institute (TSRI) and, separately, Founder and Director of The Neuroscience Institute. Significant contributions in biophysics, protein chemistry, immunology, cell biology, and neurobiology. Studies on the structure and diversity of antibodies led to the Nobel Prize for Physiology or Medicine in 1972. Vincent P. Mauro, Ph.D., is Associate Professor in the Department of Neurobiology at TSRI. Dr. Mauro and his colleagues have developed selection methodologies to identify IRES elements in mammalian cells and in yeast. He has also demonstrated that powerful synthetic Translational Enhancer Elements (TEEs) can be generated by linking individual IRES elements.

4. Scripps – Our Equity Partner • Scripps Partnership: • 3 Year Laboratory Funding Agreement in place establishing a relationship with Promosome and the laboratories of Drs. Edelman and Mauro; • Promosome has exclusive, sole worldwide rights to license discoveries from the laboratory. • Scripps 20+% founder’s interest, subject to normal dilution – no future royalties.

5. Proprietary Technology Advantage • Two Key Components: • Selection Technology • Translational Enhancer Elements (“TEE”s), including IRESes • Substantial Enhancements For: • Protein production (90% of Promosomes Current Effort) • DNA vaccines (10% of Promosomes Current Effort) • Future Opportunities: • Special reagents • Therapeutics • Molecular diagnostics

6. Technology Basics • Our approach to enhancing protein synthesis involves maximizing translation initiation. • Synthetic Translation Enhancement Elements (TEEs) • Multiple elements increase number of binding sites • More ribosomes are “captured” • More protein is created (5-10 Fold Increase of pg/c/d) • Development Results Promise Industry Leadership • Protein boost of up to 25 fold have been achieved with certain proteins • Most recent data has demonstrated 4-5 fold increase (100ml scale) in industry relevant CHO-S lines • Works in a variety of mammalian cell lines • Works in non-mammalian yeast cell lines

7. The Biotech Industry Challenge Constant Need to Optimize Protein Manufacturing Capacity Repeated Demand for Next Generation of Bioproduction Enabling Technologies Translational Enhancement 1 Promoter Transcription Technologies Cell Line Improvements 100’s 10 Cell Culture Process Development 1000’s 100’s

8. The Biotech Industry Challenge Constant Need to Optimize Protein Manufacturing Capacity Repeated Demand for Next Generation of Bioproduction Enabling Technologies Translational Enhancement Promoter Transcription Technologies YIELD Cell Line Improvements Cell Culture / Process Development TIME

9. The Biotech Industry Challenge Constant Need to Optimize Protein Manufacturing Capacity Repeated Demand for Next Generation of Bioproduction Enabling Technologies Translational Enhancement Promoter Transcription Technologies YIELD Cell Line Improvements Cell Culture / Process Development TIME

10. The Biotech Industry Relief • Lower Capital Cost (New SS) • Improved Return (Existing SS) • Decreased Cost of Goods • Increased Margins • Greater Speed to Market • Competitive Advantage g/l • Enablement of Shelved • “Hard to Make” Proteins

11. Market Advantage • Our translational approach has been presented to leading Bio-Process Service firms and major Biotech players. The general consensus has been: The Most Advanced Molecular Solutions Currently Available Excellent Market Timing Fully Complementary to Previous Industry Advances Purveyors and End Users of Transcriptional Approaches are All Potential Collaborators or Customers Solid IP and Freedom to Practice

12. Investment Promosome expects to achieve revenues of $16 M by Year 3 Pretax margins anticipated at 35% Raised $1.9 Million in 2003 Institutional investors (17.8%) Private entities (19.8%) Management & board (18.9%) Scientific team (21.2%) Scripps (21.2%) plus consultants (1% as warrants) $7 M in Series B Preferred equity All Series A shareholders plus three new investors have combined to invest $2M Series B “Bridge” in April of 2007. The balance of the B round is anticipated to close Q1 2008.

13. Summary Unique model Drives early revenue while positioning company for higher-value therapeutic development World-Class Scientific Team Partnership & Continuing Support from Scripps Exceptional Market Timing Solid Industry Management Grants & Prior Funding, Lower Investment Risk Early Adopters Being Positioned